Sandu Pharmaceuticals (BOM:524703) Cyclically Adjusted Revenue per Share: ₹89.50 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524703 Sandu Pharmaceuticals Ltd BOM:524703
71 GF Score
Price ₹37.74
GF Value ₹53.47
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sandu Pharmaceuticals Cyclically Adjusted Revenue per Share?

Sandu Pharmaceuticals BOM:524703 -1.20% 71 Cyclically Adjusted Revenue per Share is ₹89.50 as of Jun. 2026. GuruFocus rates BOM:524703 with a GF Score™ of 71/100 and a GF Value™ of ₹53.47 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sandu Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹16.964. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹89.50 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Sandu Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sandu Pharmaceuticals was 4.50% per year. The lowest was 1.40% per year. And the median was 2.60% per year.

As of today (2026-08-31), Sandu Pharmaceuticals's current stock price is ₹37.74. Sandu Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹89.50. Sandu Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.42.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sandu Pharmaceuticals was 0.94. The lowest was 0.34. And the median was 0.64.


Sandu Pharmaceuticals  (BOM:524703) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sandu Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=37.74/89.50
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sandu Pharmaceuticals was 0.94. The lowest was 0.34. And the median was 0.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sandu Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Sandu Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sandu Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandu Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Sandu Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.62 84.73 86.64 86.98 88.40

Sandu Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.87 88.72 88.82 88.40 89.50

BOM:524703 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sandu Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandu Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandu Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sandu Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:524703
71GF Score
Sandu Pharmaceuticals Ltd BOM:524703
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandu Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sandu Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=16.964/167.3573*167.3573
=16.964

Current CPI (Jun. 2026) = 167.3573.

Sandu Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 15.761 105.961 24.893
201612 15.754 105.196 25.063
201703 14.984 105.196 23.838
201706 12.882 107.109 20.128
201709 26.402 109.021 40.529
201712 15.836 109.404 24.225
201803 17.134 109.786 26.119
201806 15.748 111.317 23.676
201809 17.278 115.142 25.113
201812 19.979 115.142 29.039
201903 16.584 118.202 23.481
201906 17.528 120.880 24.267
201909 16.778 123.175 22.796
201912 18.551 126.235 24.594
202003 15.419 124.705 20.693
202006 15.355 127.000 20.234
202009 24.324 130.118 31.285
202012 22.042 130.889 28.183
202103 19.782 131.771 25.124
202106 19.897 134.084 24.834
202109 22.135 135.847 27.269
202112 20.481 138.161 24.809
202203 13.862 138.822 16.711
202206 17.253 142.347 20.284
202209 17.933 144.661 20.747
202212 18.104 145.763 20.786
202303 15.300 146.865 17.435
202306 17.771 150.280 19.790
202309 17.192 151.492 18.992
202312 17.682 152.924 19.351
202403 16.069 153.035 17.573
202406 17.361 155.789 18.650
202409 18.406 157.882 19.511
202412 18.852 158.323 19.928
202503 14.656 157.552 15.568
202506 17.200 159.755 18.018
202509 18.149 162.289 18.716
202512 19.433 163.281 19.918
202603 15.533 164.272 15.825
202606 16.964 167.357 16.964

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹89.50 mean?
Sandu Pharmaceuticals (BOM:524703) has a Cyclically Adjusted Revenue per Share of ₹89.50 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sandu Pharmaceuticals and its competitors.
Is Sandu Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Sandu Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹89.50. Overall, Sandu Pharmaceuticals has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sandu Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Sandu Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹89.50 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sandu Pharmaceuticals and its competitors. Sandu Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹89.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandu Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sandu Pharmaceuticals (BOM:524703) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹53.47, compared to a current price of ₹37.74 — trading 29.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹89.50. Sandu Pharmaceuticals' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sandu Pharmaceuticals (BOM:524703), the current Cyclically Adjusted Revenue per Share is ₹89.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sandu Pharmaceuticals (BOM:524703) Overvalued in 2026?

Based on GuruFocus' analysis, Sandu Pharmaceuticals stock appears to be undervalued. The current stock price of ₹37.74 is trading 29.4% below its estimated GF Value™ of ₹53.47. GuruFocus considers Sandu Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BOM:524703:

  • Cyclically Adjusted Revenue per Share: ₹89.50
  • GF Value™: ₹53.47 vs. price of ₹37.74 (29.4% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the BOM:524703 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sandu Pharmaceuticals Business Description

Address D. K. Sandu Marg, Sandu Nagar, Chembur, Mumbai, MH, IND, 400 071
Sandu Pharmaceuticals Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and sales of Ayurvedic pharmaceutical products.
71GF Score

Get the complete analysis for BOM:524703

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹37.74
Price
₹53.47
GF Value